文献
601. Barrington KJ, Finer NN. Inhaled nitric oxide for respiratory failure in preterm infants. Cochrane Database Syst Rev 2006; 1: CD000509.
602. Shah PS, Ohlsson A. Sildenafil for pulmonary hypertension in neonates. Cochrane Database Syst Rev 2007; 3: CD005494.
603. Bassler D, Kreutzer K, McNamara P, et al. Milrinone for persistent pulmonary hypertension of the newborn (Protocol). Cochrane Database Syst Rev
2009; 2: CD007802.
604. Ho JJ, Rasa G. Magnesium sulfate for persistent pulmonary hypertension of the newborn. Cochrane Database Syst Rev 2007; 3: CD005588.
605. UK Collaborative Trial Group. UK collaborative randmised trial of neonatal extracorporeal membranous oxygenation. Lancet 1996; 348: 75-82.
606. Wolf GK, Arnold JH. Extracorporeal membranous oxygenation. Manual of Naonatal Care 6th edn. Philadelphia, PA: Lippincott 2008: 346-352.
607. 久田欣一，飯沼武，有水昇，他（日本アイソトープ協会医学・薬学部会核医学イメージング規格化専門委員会）．核医学イメージングのための小児への放射線
医薬品投与量に関する勧告. Radioisotopes 1988; 37: 627-632.
608. Valentin J . Radiation dose to patients from radiopharmaceuticals, ICRP publication 80:(addendum 2 to ICRP publication 53)approved by commission
in September 1997. Ann ICRP 1998; 28: 1-123.
609. Thompson RC, Cullom SJ. Issues regarding radiation dosage of cardiac nuclear and radiography procedures. J Nucl Cardiol 2006; 13: 19-23.
610. 近藤千里. 小児心血管画像検査に伴う放射線被曝. 日小循誌 2007; 23: 434-439.
611. 循環器病の診断と治療に関するガイドライン．心臓核医学検査ガイドライン（2010年改訂版）．http://www.j-circ. or.jp/guideline/pdf/JCS2005_tamaki_h.pdf
（平成2011年8月14日閲覧）.
612. 唐澤賢祐，鮎沢衛，能登信孝，他．川崎病冠動脈狭窄性病変における99mTcTetrofosmin心筋血流イメージングの至適撮像方法に関する検討. J Cardiol
1997; 30: 331-339.
613. Germano G, Erel J, Lewin H, et al. Automatic quantitation of regional myocardial wall motion and thickening from gated technetium-99m sestamibi
myocardial perfusion singlephoton emission computed tomography. J Am Coll Cardiol 1997; 30: 1360-1367.
614. Monzen H, Hara M, Hirata M, et al. Exploring a technique for reducing the influence of scattered rays from surrounding organs to the heart during the
myocardial perfusion scintigraphy technetium-99m sestamibi and technetium-99m tetrofosmin. Ann Nucl Med 2006; 20: 705-710.
615. Kanamaru H, Karasawa K, Ichikawa R, et al. Dual myocardial scintigraphy mismatch in an infant with Bland-White-Garland syndrome. Int J Cardiol
2009; 135: e1-3.
616. Hoshina M, Shiraishi H, Igarashi H, et al. Efficacy of iodine-123-15-(p-iodophenyl)-3-R, S-methylpentadecanoic acid single photon emission computed
tomography imaging in detecting myocardial ischemia in children with Kawasaki disease. Circ J 2003; 67: 663-666.
617. Kondo C, Nakazawa M, Kusakabe K, et al. Myocardial dysfunction and depressed fatty acid metabolism in patients with cyanotic congenital heart
disease. J Nucl Cardiol 1996; 3: 30-36.
618. Terai H, Shimizu M, Ino H, et al. Changes in cardiac sympathetic nerve innervation and activity in pathophysiologic transition from typical to end-stage
hypertrophic cardiomyopathy. J Nucl Med 2003; 44: 1612-1617.
619. Kondo C, Nakazawa M, Momma K, et al. Sympathetic denervation and reinnervation after arterial switch operation for complete transposition.
Circulation 1998; 97: 2414-2419.
620. 唐澤賢祐，鮎沢衛，能登信孝，住友直方，他．小児期慢性心不全における心交感神経機能に関する検討：Iodine-123 metaiodobenzylguanidine 心筋シンチ
グラフィーを用いて. J Cardiol 2000; 36: 387-395.
621. Matsuura H, Ishikita T, Yamamoto S, et al. Gallium-67 myocardial imaging for the detection of myocarditis in the acute phase of Kawasaki disease
(mucocutaneous lymph node syndrome): the usefulness of single photon emission computed tomography. Br Heart J 1987; 58: 385-392.
622. Yoshibayashi M, Tamaki N, Nishioka K, et al. Regional myocardial perfusion and metabolism assessed by positron emission tomography in children
with Kawasaki disease and significance of abnormal Q waves and their disappearance. Am J Cardiol 1991; 68: 1638-1645.
623. Prabhu AS, Singh TP, Morrow WR, et al. Safety and efficacy of intravenous adenosine for pharmacologic stress testing in children with aortic valve
disease or Kawasaki disease. Am J Cardiol 1999; 83: 284-286, A286.
624. Hauser M, Bengel FM, Kuhn A, et al. Myocardial blood flow and flow reserve after coronary reimplantation in patients after arterial switch and ross
operation. Circulation 2001; 103: 1875-1880.
625. 山崎純一，西村恒彦，西村重敬，他．SUNY4001（アデノシン）負荷201TL心筋シンチグラフィの虚血診断能および安全性- 臨床第III 相試験- 核医学 2004;
41: 133-142.
626. Karasawa K, Ayusawa M, Noto N, et al. Optimum protocol of technetium-99m tetrofosmin myocardial perfusion imaging for the detection of coronary
stenosis lesions in Kawasaki disease. J Cardiol 1997; 30: 331-339.
627. Kondo C, Hiroe M, Nakanishi T, et al. Detection of coronary artery stenosis in children with Kawasaki disease. Usefulness of pharmacologic stress
201Tl myocardial tomography. Circulation 1989; 80: 615-624.
628. Hamamichi Y, Ichida F, Tsubata S, et al. Dobutamine stress radionuclide ventriculography reveals silent myocardial dysfunction in Kawasaki disease.
Circ J 2002; 66: 63-69.
629. 唐澤賢祐，鮎沢 衛，能登信孝，他．川崎病後冠状動脈狭窄に対するドブタミン負荷Thallium-201 myocardial SPECT.日小循誌 1994; 9: 723-733.
630. 中田智明，渡辺重行，松尾仁司，他．負荷心筋シンチグラフィに関する安全指針．心臓核医学 2008; 38: 6-10.
631. Yamamoto S, Matsuura H, Umezawa T, et al. Dipyridamole-induced ischemia in a child with jeopardized collaterals after Kawasaki syndrome.
Jpn Heart J 1990; 31: 867-874.
632. Mertes H, Sawada SG, Ryan T, et al. Symptoms, adverse effects, and complications associated with dobutamine stress echocardiography.
Experience in 1118 patients. Circulation 1993; 88: 15-19.
633. 日本肝移植研究会. 肝移植症例登録報告. 移植 2010; 45: 621-632.
634. 日本臨床腎移植学会，移植学会．腎臓移植臨床登録集計報告（2010）-3 2009年経過追跡調査結果．移植 2010; 45: 608-620.
635. 白石武史，他．小児肺移植－世界の事情と日本の展望．今日の移植 2010; 23: 534-542.
636. 小野安生，福嶌教偉．小児期拡張型心筋症の自然予後．心臓移植対象例における検討．Annual Review 2008: 297-301.
637. 服部新三郎. 小児腎不全の疫学調査. 腹膜透析 2005; 21: 1315-1322.
638. 日本小腸移植研究会. 本邦小腸移植症例登録報告. 移植2010; 45: 652-654.
639. Dew MA, Dabbs AD, Myakovsky L, et al. Metaanalysis of medical regimen adherence outcomes in pediatric solid organ transplantation.
Transplantation 2009; 88: 736-746.
640. Kirk R, Edwards LB, Aurora P, et al. Registry of the International Society for Heart and Lung Transplantation: twelfth official pediatric heart
transplantation report-2009. J Heart Lung Transplant 2009; 28: 993-1006.
641. Gossett JG, Canter CE, Zheng J, et al. Decline in rejection in the first year after pediatric cardiac transplantation: a multiinstitutional study.
J Heart Lung Transplant 2010; 29: 625-632.
642. Schmauss D, Weis M. Cardiac allograft vasculopathy: recent developments. Circulation 2008; 117: 2131-2141.
643. Russo LM, Webber SA. Pediatric heart transplantation: immunosuppression and its complications. Curr Opin Cardiol 2004; 19: 104-109.
644. Reddy SC, Laughlin K, Webber SA. Immunosuppression in Pediatric Heart Transplantation: 2003 and Beyond. Curr Treat Options Cardiovasc
Med 2003; 5: 417-428.
645. Lobach NE, Pollock-BarZiv SM, West LJ, et al. Sirolimus immunosuppression in pediatric heart transplant recipients: a single-center experience.
J Heart Lung Transplant 2005; 24: 184-189.
646. Sarwal MM. Out with the old, in with the new: immunosuppression minimization in children. Curr Opin Organ Transplant 2008; 13: 513-521.
647. Patel J , Kobashigawa JA. Minimization of immunosuppression. Transplant Immunol 2008; 20: 48-54.
648. Singh TP, Faber C, Blume ED, et al. Safety and early outcomes using a corticosteroid - avoidance immunosuppression protocol in pediatric heart
transplant recipients. J Heart Lung Transplant 2010; 29: 517-522.
649. Simmonds J, Dewar C, Dawkins H, et al. Tacrolimus in pediatric heart transplantation: ameliorated side effects in the steroid-free, statin era. Clin
Transplant 2009; 23: 415-419.
650. Uber P, Mehra M. Induction therapy in heart transplantation: is there a role? J Heart Lung Transplant 2007; 26: 205-209.
651. Ensor CR, Cahoon WD, Hess ML, et al. Induction immunosuppression for orthotopic heart transplantation: a review. Prog Transplant 2009; 19:
333-342.
652. Boucek RJ, Naftel D, Boucek MM, et al. Induction immunotherapy in pediatric heart transplant recipients: a multicenter study. J Heart Lung
Transplant 1999; 18: 460-469.
653. Di Fillippo S, Boissonnat P, Sassolas F, et al. Rabbit antithymocyte globulin as induction immunotherapy in pediatric heart transplantation.
Transplantation 2003; 75: 354-358.
654. Gajarski RJ, Blume ED, Schchtman K, et al. Use of induction agents and incidence of infection and malignancy following pediatric heart
transplantation. J Heart Lung Transplant 2010; 29: 2S-S70.
655. Pollock-BarZiv SM, Allain-Rooney T,Manlhiot C, et al. Continuous infusion of thymoglobulin for induction therapy in pediatric heart transplant
recipients; experience and outcomes with a novel strategy for administration. Pediatr Transplant 2009; 13: 585-589.
656. Flaman F, Zieroth S, Rao V, et al. Basiliximab versus rabbit anti-thymocyte globulin for induction therapy in patients after heart transplantation.
J Heart Lung Transplant 2006; 25: 1358-1362.
657. Mehra MR, Zucker MJ, Wagoner L, et al. A multicenter, prospective, randomized, double-blind trial of basiliximab in heart transplantation. J Heart
Lung Transplant 2005; 24: 1297-1304.
658. Mattei MF, Redonnet M, Gandjbakhch I, et al. Lower risk of infectious deaths in cardiac transplant patients receiving basiliximab versus
anti-thymocyte globulin as induction therapy. J Heart Lung Transplant 2007; 26: 693-699.
659. Grundy N, Simmonds J, Dawkins H, et al. Pre-implantation basiliximab reduces incidence of early acute rejection in pediatric heart transplantation.
J Heart Lung Transplant 2009; 28: 1279-1284.
660. Leonard H, Hornung T, ParryG, et al. Pediatric cardiac transplant: results using a steroid-free maintenance regimen. Pediatr Transplant 2003; 7: 59-63.
661. Fullerton DA, Campbell DN, Jones SD, et al. Heart transplantation in children and young adults: early and intermediate-term results. Ann Thorac
Surg 1995; 59: 804-811.
662. Smith RR, Wray J, Khaghani A, et al. Ten year survival after paediatric heart transplantation: a single centre experience. Eur J Cardiothorac Surg
2005; 27: 790-794.
663. Hmiel SP, Canter C, Shepherd R, et al. Limitations of recipients. Pediatr Transplant 2007; 11: 524-529.
664. Filler G, Rocha de Barros V, Jagger JE, et al. Cyclosporin twice or three times daily dosing in pediatric transplant patients-It is not the same! Pediatr
Transplant 2006; 10: 953-956.
665. Webber SA. The current state of, and future prospects for, cardiac transplantation in children. Cardiol Young 2003; 13: 64-83.
666. Girnita DM, Webber SA, Ferrell R, et al. Disparate distribution of 16 candidate single nucleotide polymorphisms among racial and ethnic groups in
pediatric heart transplant patients. Transplantation 2006; 82: 1774-1780.
667. Zheng HX, Webber SA, Zeevi A, et al. The impact of pharmacogenomic factors on steroid weaning in pediatric heart transplant patients using logistic
regression analysis. Pediatr Transplant 2004; 8: 551-557.
668. Temple-Smolkin R, Burckart GJ, Zeevi A. Gene polymorphisms and pharmacogenomics. In Pediatric solid organ transplantation, edn 2nd. By Fine
RN, Webber SA, Olthoff KM, et al. Malden: Blackwell Publishing 2007.
669. Knight SR, Morris PJ. Does the evidence support the use of mycophenolate mofetil therapeutic drug monitoring in clinical practice? A systematic
review. Transplantation 2008; 85: 1675-1685.
670. Abe T, Ichimaru N, Okumi M, et al. Pregnancy after renal transplantation: A single-center experienceInternational Journal of Urology 2008;
15: 587-592.
671. Tönshoffa B, David-Netob E, Ettengerc R, et al. Pediatric aspects of therapeutic drug monitoring of mycophenolic acid in renal transplantation.
Transplantation Reviews 2011; 25:78-89.
672. Ohmann EL, Burckart GJ, Brooks MM, et al. Genetic polymorphisms influence mycophenolate mofetilrelated adverse events in pediatric heart
transplant patients. J Heart Lung Transplant 2010; 29: 509-516.
673. Massari P, Duro-Garcia V, Giron F, et al. Safety assessment of the conversion from mycophenolate mofetil to entericcoated mycophenolate sodium
in stable renal transplant recipients. Transplant Proc 2005; 37: 916-919.
674. Yi T, Cuchara L, Wang Y, et al. Human allograft arterial injury is ameliorated by sirolimus and cyclosporine and correlates with suppression of
interferon-gamma. Transplantation 2006; 81: 559-566.
675. Raichlin E, Bae JH, Khalpey Z, et al. Conversion to sirolimus as primary immunosuppression attenuates the progression of allograft vasculopathy after
cardiac transplantation. Circulation 2007; 116: 2726-2733.
676. Pauly D, Starling R, Kobashigawa J, et al. Heart transplant recipients treated with everolimus have less increase in intimal thickness vs MMF,
Irrespective of lipid values. J Heart Lung Transplant 2011; 30: S26.
677. Balfour IC, Scrun SW, Wood EG, et al. Early renal benefit of rapamycin combined with reduced calcineurin inhibitor dose in pediatric heart
transplantation patients. J Heart Lung Transplant 2006; 25: 518-522.
678. Chinnock RE, Baum MF, Larsen R, et al. Rejection management and long-term surveillance of the pediatric heart transplant recipient: the Loma Linda
experience. J Heart Lung Transplant 1993; 12 (suppl): S255-S264.
679. Feingold BF, Olesnevich P, Zeevi A, et al. Survival in allosensitized children after listing for cardiac transplantation. J Heart Lung Transplant 2007; 26:
565-571.
680. Pollock-BarZiv SM, den Hollander N, Ngan BY, et al. Pediatric heart transplantation in human leukocyte antigen sensitized patients: evolving
management and assessment of intermediate-term outcomes in a high-risk population. Circulation 2007; 116(11 Suppl): I172-I178.
681. Holt DB, Lublin DM, Phelan DL, et al. Mortality and morbidity in pre-sensitized pediatric heart transplant recipients with a positive donor crossmatch
utilizing perioperative plasmapheresis and cytolytic therapy. J Heart Lung Transplant 2007; 26: 876-882.
682. Dipchand AI, BarZiv SM, Manlhiot C, et al. Equivalent Outcomes for Pediatric Heart Transplantation Recipients: ABO-Blood Group Incompatible
versus ABO-Compatible. Am J Transplant 2010; 10: 389-397.
683. Kaposztas Z, Podder H, Mauiyyedi S, et al. Impact of rituximab therapy for treatment of acute humoral rejection. Clin Transplant 2009; 23: 63-73.
684. Everly JJ, Walsh RC, Alloway RR, et al. Proteasome inhibition for antibody-mediated rejection. Curr Opin Organ Transplant 2009; 14: 662-666.
685. Morrow WR, Frazier E, Mahle W, et al. Proteasome inhibitor-based therapy for antibody mediated rejection in pediatric heart transplantation. Am
J Transplant 2010; 10(Supp 4): 93.
686. Kirklin JK, George JF, McGriffin DC, et al. Total lymphoid irradiation: is there a role in pediatric heart transplantation? J Heart Lung Transplant 1993;
12: S293-S300.
687. Kirklin JK, Brown RN, Huang ST, et al. Rejection with hemodynamic compromise: objective evidence for efficacy of photopheresis. J Heart Lung
Transplant 2006; 25: 283-288.
688. Russell-Jones R. Shedding light on photopheresis. Lancet 2001; 357: 820.
689. George JF, Gooden CW, Guo L, et al. Role for CD4(+) CD25(+) T cells in inhibition of graft rejection by photopheresis. J Heart Lung Transplant 2008;
27: 616-622.
690. Baker EJ, Formularly, Pediatric Cardiology, 3rd ed Anderson RH, et al ed. Churchill Livingstone/ Elsevier Philadelphia, PA 2009: 1299-1303.
602. Shah PS, Ohlsson A. Sildenafil for pulmonary hypertension in neonates. Cochrane Database Syst Rev 2007; 3: CD005494.
603. Bassler D, Kreutzer K, McNamara P, et al. Milrinone for persistent pulmonary hypertension of the newborn (Protocol). Cochrane Database Syst Rev
2009; 2: CD007802.
604. Ho JJ, Rasa G. Magnesium sulfate for persistent pulmonary hypertension of the newborn. Cochrane Database Syst Rev 2007; 3: CD005588.
605. UK Collaborative Trial Group. UK collaborative randmised trial of neonatal extracorporeal membranous oxygenation. Lancet 1996; 348: 75-82.
606. Wolf GK, Arnold JH. Extracorporeal membranous oxygenation. Manual of Naonatal Care 6th edn. Philadelphia, PA: Lippincott 2008: 346-352.
607. 久田欣一，飯沼武，有水昇，他（日本アイソトープ協会医学・薬学部会核医学イメージング規格化専門委員会）．核医学イメージングのための小児への放射線
医薬品投与量に関する勧告. Radioisotopes 1988; 37: 627-632.
608. Valentin J . Radiation dose to patients from radiopharmaceuticals, ICRP publication 80:(addendum 2 to ICRP publication 53)approved by commission
in September 1997. Ann ICRP 1998; 28: 1-123.
609. Thompson RC, Cullom SJ. Issues regarding radiation dosage of cardiac nuclear and radiography procedures. J Nucl Cardiol 2006; 13: 19-23.
610. 近藤千里. 小児心血管画像検査に伴う放射線被曝. 日小循誌 2007; 23: 434-439.
611. 循環器病の診断と治療に関するガイドライン．心臓核医学検査ガイドライン（2010年改訂版）．http://www.j-circ. or.jp/guideline/pdf/JCS2005_tamaki_h.pdf
（平成2011年8月14日閲覧）.
612. 唐澤賢祐，鮎沢衛，能登信孝，他．川崎病冠動脈狭窄性病変における99mTcTetrofosmin心筋血流イメージングの至適撮像方法に関する検討. J Cardiol
1997; 30: 331-339.
613. Germano G, Erel J, Lewin H, et al. Automatic quantitation of regional myocardial wall motion and thickening from gated technetium-99m sestamibi
myocardial perfusion singlephoton emission computed tomography. J Am Coll Cardiol 1997; 30: 1360-1367.
614. Monzen H, Hara M, Hirata M, et al. Exploring a technique for reducing the influence of scattered rays from surrounding organs to the heart during the
myocardial perfusion scintigraphy technetium-99m sestamibi and technetium-99m tetrofosmin. Ann Nucl Med 2006; 20: 705-710.
615. Kanamaru H, Karasawa K, Ichikawa R, et al. Dual myocardial scintigraphy mismatch in an infant with Bland-White-Garland syndrome. Int J Cardiol
2009; 135: e1-3.
616. Hoshina M, Shiraishi H, Igarashi H, et al. Efficacy of iodine-123-15-(p-iodophenyl)-3-R, S-methylpentadecanoic acid single photon emission computed
tomography imaging in detecting myocardial ischemia in children with Kawasaki disease. Circ J 2003; 67: 663-666.
617. Kondo C, Nakazawa M, Kusakabe K, et al. Myocardial dysfunction and depressed fatty acid metabolism in patients with cyanotic congenital heart
disease. J Nucl Cardiol 1996; 3: 30-36.
618. Terai H, Shimizu M, Ino H, et al. Changes in cardiac sympathetic nerve innervation and activity in pathophysiologic transition from typical to end-stage
hypertrophic cardiomyopathy. J Nucl Med 2003; 44: 1612-1617.
619. Kondo C, Nakazawa M, Momma K, et al. Sympathetic denervation and reinnervation after arterial switch operation for complete transposition.
Circulation 1998; 97: 2414-2419.
620. 唐澤賢祐，鮎沢衛，能登信孝，住友直方，他．小児期慢性心不全における心交感神経機能に関する検討：Iodine-123 metaiodobenzylguanidine 心筋シンチ
グラフィーを用いて. J Cardiol 2000; 36: 387-395.
621. Matsuura H, Ishikita T, Yamamoto S, et al. Gallium-67 myocardial imaging for the detection of myocarditis in the acute phase of Kawasaki disease
(mucocutaneous lymph node syndrome): the usefulness of single photon emission computed tomography. Br Heart J 1987; 58: 385-392.
622. Yoshibayashi M, Tamaki N, Nishioka K, et al. Regional myocardial perfusion and metabolism assessed by positron emission tomography in children
with Kawasaki disease and significance of abnormal Q waves and their disappearance. Am J Cardiol 1991; 68: 1638-1645.
623. Prabhu AS, Singh TP, Morrow WR, et al. Safety and efficacy of intravenous adenosine for pharmacologic stress testing in children with aortic valve
disease or Kawasaki disease. Am J Cardiol 1999; 83: 284-286, A286.
624. Hauser M, Bengel FM, Kuhn A, et al. Myocardial blood flow and flow reserve after coronary reimplantation in patients after arterial switch and ross
operation. Circulation 2001; 103: 1875-1880.
625. 山崎純一，西村恒彦，西村重敬，他．SUNY4001（アデノシン）負荷201TL心筋シンチグラフィの虚血診断能および安全性- 臨床第III 相試験- 核医学 2004;
41: 133-142.
626. Karasawa K, Ayusawa M, Noto N, et al. Optimum protocol of technetium-99m tetrofosmin myocardial perfusion imaging for the detection of coronary
stenosis lesions in Kawasaki disease. J Cardiol 1997; 30: 331-339.
627. Kondo C, Hiroe M, Nakanishi T, et al. Detection of coronary artery stenosis in children with Kawasaki disease. Usefulness of pharmacologic stress
201Tl myocardial tomography. Circulation 1989; 80: 615-624.
628. Hamamichi Y, Ichida F, Tsubata S, et al. Dobutamine stress radionuclide ventriculography reveals silent myocardial dysfunction in Kawasaki disease.
Circ J 2002; 66: 63-69.
629. 唐澤賢祐，鮎沢 衛，能登信孝，他．川崎病後冠状動脈狭窄に対するドブタミン負荷Thallium-201 myocardial SPECT.日小循誌 1994; 9: 723-733.
630. 中田智明，渡辺重行，松尾仁司，他．負荷心筋シンチグラフィに関する安全指針．心臓核医学 2008; 38: 6-10.
631. Yamamoto S, Matsuura H, Umezawa T, et al. Dipyridamole-induced ischemia in a child with jeopardized collaterals after Kawasaki syndrome.
Jpn Heart J 1990; 31: 867-874.
632. Mertes H, Sawada SG, Ryan T, et al. Symptoms, adverse effects, and complications associated with dobutamine stress echocardiography.
Experience in 1118 patients. Circulation 1993; 88: 15-19.
633. 日本肝移植研究会. 肝移植症例登録報告. 移植 2010; 45: 621-632.
634. 日本臨床腎移植学会，移植学会．腎臓移植臨床登録集計報告（2010）-3 2009年経過追跡調査結果．移植 2010; 45: 608-620.
635. 白石武史，他．小児肺移植－世界の事情と日本の展望．今日の移植 2010; 23: 534-542.
636. 小野安生，福嶌教偉．小児期拡張型心筋症の自然予後．心臓移植対象例における検討．Annual Review 2008: 297-301.
637. 服部新三郎. 小児腎不全の疫学調査. 腹膜透析 2005; 21: 1315-1322.
638. 日本小腸移植研究会. 本邦小腸移植症例登録報告. 移植2010; 45: 652-654.
639. Dew MA, Dabbs AD, Myakovsky L, et al. Metaanalysis of medical regimen adherence outcomes in pediatric solid organ transplantation.
Transplantation 2009; 88: 736-746.
640. Kirk R, Edwards LB, Aurora P, et al. Registry of the International Society for Heart and Lung Transplantation: twelfth official pediatric heart
transplantation report-2009. J Heart Lung Transplant 2009; 28: 993-1006.
641. Gossett JG, Canter CE, Zheng J, et al. Decline in rejection in the first year after pediatric cardiac transplantation: a multiinstitutional study.
J Heart Lung Transplant 2010; 29: 625-632.
642. Schmauss D, Weis M. Cardiac allograft vasculopathy: recent developments. Circulation 2008; 117: 2131-2141.
643. Russo LM, Webber SA. Pediatric heart transplantation: immunosuppression and its complications. Curr Opin Cardiol 2004; 19: 104-109.
644. Reddy SC, Laughlin K, Webber SA. Immunosuppression in Pediatric Heart Transplantation: 2003 and Beyond. Curr Treat Options Cardiovasc
Med 2003; 5: 417-428.
645. Lobach NE, Pollock-BarZiv SM, West LJ, et al. Sirolimus immunosuppression in pediatric heart transplant recipients: a single-center experience.
J Heart Lung Transplant 2005; 24: 184-189.
646. Sarwal MM. Out with the old, in with the new: immunosuppression minimization in children. Curr Opin Organ Transplant 2008; 13: 513-521.
647. Patel J , Kobashigawa JA. Minimization of immunosuppression. Transplant Immunol 2008; 20: 48-54.
648. Singh TP, Faber C, Blume ED, et al. Safety and early outcomes using a corticosteroid - avoidance immunosuppression protocol in pediatric heart
transplant recipients. J Heart Lung Transplant 2010; 29: 517-522.
649. Simmonds J, Dewar C, Dawkins H, et al. Tacrolimus in pediatric heart transplantation: ameliorated side effects in the steroid-free, statin era. Clin
Transplant 2009; 23: 415-419.
650. Uber P, Mehra M. Induction therapy in heart transplantation: is there a role? J Heart Lung Transplant 2007; 26: 205-209.
651. Ensor CR, Cahoon WD, Hess ML, et al. Induction immunosuppression for orthotopic heart transplantation: a review. Prog Transplant 2009; 19:
333-342.
652. Boucek RJ, Naftel D, Boucek MM, et al. Induction immunotherapy in pediatric heart transplant recipients: a multicenter study. J Heart Lung
Transplant 1999; 18: 460-469.
653. Di Fillippo S, Boissonnat P, Sassolas F, et al. Rabbit antithymocyte globulin as induction immunotherapy in pediatric heart transplantation.
Transplantation 2003; 75: 354-358.
654. Gajarski RJ, Blume ED, Schchtman K, et al. Use of induction agents and incidence of infection and malignancy following pediatric heart
transplantation. J Heart Lung Transplant 2010; 29: 2S-S70.
655. Pollock-BarZiv SM, Allain-Rooney T,Manlhiot C, et al. Continuous infusion of thymoglobulin for induction therapy in pediatric heart transplant
recipients; experience and outcomes with a novel strategy for administration. Pediatr Transplant 2009; 13: 585-589.
656. Flaman F, Zieroth S, Rao V, et al. Basiliximab versus rabbit anti-thymocyte globulin for induction therapy in patients after heart transplantation.
J Heart Lung Transplant 2006; 25: 1358-1362.
657. Mehra MR, Zucker MJ, Wagoner L, et al. A multicenter, prospective, randomized, double-blind trial of basiliximab in heart transplantation. J Heart
Lung Transplant 2005; 24: 1297-1304.
658. Mattei MF, Redonnet M, Gandjbakhch I, et al. Lower risk of infectious deaths in cardiac transplant patients receiving basiliximab versus
anti-thymocyte globulin as induction therapy. J Heart Lung Transplant 2007; 26: 693-699.
659. Grundy N, Simmonds J, Dawkins H, et al. Pre-implantation basiliximab reduces incidence of early acute rejection in pediatric heart transplantation.
J Heart Lung Transplant 2009; 28: 1279-1284.
660. Leonard H, Hornung T, ParryG, et al. Pediatric cardiac transplant: results using a steroid-free maintenance regimen. Pediatr Transplant 2003; 7: 59-63.
661. Fullerton DA, Campbell DN, Jones SD, et al. Heart transplantation in children and young adults: early and intermediate-term results. Ann Thorac
Surg 1995; 59: 804-811.
662. Smith RR, Wray J, Khaghani A, et al. Ten year survival after paediatric heart transplantation: a single centre experience. Eur J Cardiothorac Surg
2005; 27: 790-794.
663. Hmiel SP, Canter C, Shepherd R, et al. Limitations of recipients. Pediatr Transplant 2007; 11: 524-529.
664. Filler G, Rocha de Barros V, Jagger JE, et al. Cyclosporin twice or three times daily dosing in pediatric transplant patients-It is not the same! Pediatr
Transplant 2006; 10: 953-956.
665. Webber SA. The current state of, and future prospects for, cardiac transplantation in children. Cardiol Young 2003; 13: 64-83.
666. Girnita DM, Webber SA, Ferrell R, et al. Disparate distribution of 16 candidate single nucleotide polymorphisms among racial and ethnic groups in
pediatric heart transplant patients. Transplantation 2006; 82: 1774-1780.
667. Zheng HX, Webber SA, Zeevi A, et al. The impact of pharmacogenomic factors on steroid weaning in pediatric heart transplant patients using logistic
regression analysis. Pediatr Transplant 2004; 8: 551-557.
668. Temple-Smolkin R, Burckart GJ, Zeevi A. Gene polymorphisms and pharmacogenomics. In Pediatric solid organ transplantation, edn 2nd. By Fine
RN, Webber SA, Olthoff KM, et al. Malden: Blackwell Publishing 2007.
669. Knight SR, Morris PJ. Does the evidence support the use of mycophenolate mofetil therapeutic drug monitoring in clinical practice? A systematic
review. Transplantation 2008; 85: 1675-1685.
670. Abe T, Ichimaru N, Okumi M, et al. Pregnancy after renal transplantation: A single-center experienceInternational Journal of Urology 2008;
15: 587-592.
671. Tönshoffa B, David-Netob E, Ettengerc R, et al. Pediatric aspects of therapeutic drug monitoring of mycophenolic acid in renal transplantation.
Transplantation Reviews 2011; 25:78-89.
672. Ohmann EL, Burckart GJ, Brooks MM, et al. Genetic polymorphisms influence mycophenolate mofetilrelated adverse events in pediatric heart
transplant patients. J Heart Lung Transplant 2010; 29: 509-516.
673. Massari P, Duro-Garcia V, Giron F, et al. Safety assessment of the conversion from mycophenolate mofetil to entericcoated mycophenolate sodium
in stable renal transplant recipients. Transplant Proc 2005; 37: 916-919.
674. Yi T, Cuchara L, Wang Y, et al. Human allograft arterial injury is ameliorated by sirolimus and cyclosporine and correlates with suppression of
interferon-gamma. Transplantation 2006; 81: 559-566.
675. Raichlin E, Bae JH, Khalpey Z, et al. Conversion to sirolimus as primary immunosuppression attenuates the progression of allograft vasculopathy after
cardiac transplantation. Circulation 2007; 116: 2726-2733.
676. Pauly D, Starling R, Kobashigawa J, et al. Heart transplant recipients treated with everolimus have less increase in intimal thickness vs MMF,
Irrespective of lipid values. J Heart Lung Transplant 2011; 30: S26.
677. Balfour IC, Scrun SW, Wood EG, et al. Early renal benefit of rapamycin combined with reduced calcineurin inhibitor dose in pediatric heart
transplantation patients. J Heart Lung Transplant 2006; 25: 518-522.
678. Chinnock RE, Baum MF, Larsen R, et al. Rejection management and long-term surveillance of the pediatric heart transplant recipient: the Loma Linda
experience. J Heart Lung Transplant 1993; 12 (suppl): S255-S264.
679. Feingold BF, Olesnevich P, Zeevi A, et al. Survival in allosensitized children after listing for cardiac transplantation. J Heart Lung Transplant 2007; 26:
565-571.
680. Pollock-BarZiv SM, den Hollander N, Ngan BY, et al. Pediatric heart transplantation in human leukocyte antigen sensitized patients: evolving
management and assessment of intermediate-term outcomes in a high-risk population. Circulation 2007; 116(11 Suppl): I172-I178.
681. Holt DB, Lublin DM, Phelan DL, et al. Mortality and morbidity in pre-sensitized pediatric heart transplant recipients with a positive donor crossmatch
utilizing perioperative plasmapheresis and cytolytic therapy. J Heart Lung Transplant 2007; 26: 876-882.
682. Dipchand AI, BarZiv SM, Manlhiot C, et al. Equivalent Outcomes for Pediatric Heart Transplantation Recipients: ABO-Blood Group Incompatible
versus ABO-Compatible. Am J Transplant 2010; 10: 389-397.
683. Kaposztas Z, Podder H, Mauiyyedi S, et al. Impact of rituximab therapy for treatment of acute humoral rejection. Clin Transplant 2009; 23: 63-73.
684. Everly JJ, Walsh RC, Alloway RR, et al. Proteasome inhibition for antibody-mediated rejection. Curr Opin Organ Transplant 2009; 14: 662-666.
685. Morrow WR, Frazier E, Mahle W, et al. Proteasome inhibitor-based therapy for antibody mediated rejection in pediatric heart transplantation. Am
J Transplant 2010; 10(Supp 4): 93.
686. Kirklin JK, George JF, McGriffin DC, et al. Total lymphoid irradiation: is there a role in pediatric heart transplantation? J Heart Lung Transplant 1993;
12: S293-S300.
687. Kirklin JK, Brown RN, Huang ST, et al. Rejection with hemodynamic compromise: objective evidence for efficacy of photopheresis. J Heart Lung
Transplant 2006; 25: 283-288.
688. Russell-Jones R. Shedding light on photopheresis. Lancet 2001; 357: 820.
689. George JF, Gooden CW, Guo L, et al. Role for CD4(+) CD25(+) T cells in inhibition of graft rejection by photopheresis. J Heart Lung Transplant 2008;
27: 616-622.
690. Baker EJ, Formularly, Pediatric Cardiology, 3rd ed Anderson RH, et al ed. Churchill Livingstone/ Elsevier Philadelphia, PA 2009: 1299-1303.
小児期心疾患における薬物療法ガイドライン
Guidelines for Drug Therapy in Pediatric Patients with Cardiovascular Diseases （ JCS2012）
Guidelines for Drug Therapy in Pediatric Patients with Cardiovascular Diseases （ JCS2012）